LIN BIOSCIENCE, INC.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
1. LBS-008
2. LBS-007
3. LBS-002
4. LBS-009
2. LBS-007
3. LBS-002
4. LBS-009
Founded Year
2016
Unified Business No.
43814765
Status
Active
Number of Employees
0
Total Paid-in
Capital
827,250,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2018)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Lin BioScience, Inc. (TPEx: 6696) is a drug development company established in 2016 focusing on advancing novel therapies and first-in-class treatments for unmet medical needs in various therapeutic areas such as ophthalmology, oncology, and metabolic diseases. Lin BioScience’s pipeline currently consists of four candidate drugs. LBS-008 treating dry age-related macular degeneration and Stargardt disease, and LBS-009 treating nonalcoholic steatohepatitis are developed by its subsidiary Belite Bio Inc. (Nasdaq: BLTE). LBS-007 treating acute leukemias and solid tumors, and LBS-002 treating glioblastoma and the metastasis are developed by Lin BioScience, inc..
